DXCM · NASDAQ · Health Care Equipment
Health Care Equipment company based in San Diego, California.
Last close, Oct 1, 2026
$86.23
Adjusted for splits and dividends
Last 12 months
+30.5%
S&P 500 +14.3% over the same dates
Market value
$32.5B
Last close × shares outstanding
Bets against the stock: 17.3M shares sold short (4.6% of shares outstanding), -2.1% vs the previous count, 5.0 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
16 sales
$8.65M sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$4.66B
+15.6% vs the year before
Net income, fiscal 2025
$836M
As reported in the annual filing
Shares outstanding
377M
As of Jul 23, 2026
In fiscal 2025 the company spent $500M buying back its own shares. Cash actually paid, from its cash-flow statement.
Officer plans to sell ~$221K of Dexcom
Planned, from payDirector sold ~$550K of Dexcom
Scheduled in advancePrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Last 12 months, adjusted daily closes
Adjusted close went from $66.08 on Oct 1, 2025 to $86.23 on Oct 1, 2026 (+30.5%). Disclosed trades in the last 12 months: 2 insider purchases, 30 insider sales (30 under pre-arranged plans), 1 Congress purchase, 2 Congress sales.
A securities lawsuit naming the company as a defendant was filed on Oct 27, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.
Prime v. DexCom, Inc., 1:25-cv-08912A securities lawsuit naming the company as a defendant was filed on Oct 9, 2024 in the U.S. District Court, S.D. California. A filing is an allegation, not a finding.
Carnes v. Dexcom Inc., 3:24-cv-01809A securities lawsuit naming the company as a defendant was filed on Oct 8, 2024 in the U.S. District Court, S.D. California. A filing is an allegation, not a finding.
Oakland County Employees' Retirement System v. Dexcom, Inc., 3:24-cv-01804Federal civil cases with nature of suit 850 (securities) filed in the last 3 years where the company is the first named defendant, from court records on CourtListener (Free Law Project). 3 cases in that period are closed and not listed. Coverage of court records is not complete, and shareholder derivative suits are not included.
Short sale volume: 53.3% of the volume reported to FINRA over the last 20 trading days was marked short, above its 1-year average of 45.4%. FINRA daily files, to Oct 2, 2026.
Fails to deliver: 20K shares (about $1.79M) were not delivered on time for settlement on Aug 26, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.
1 notice filed with state agencies, covering 319 workers in total. Employers must warn the state ahead of a plant closing or mass layoff at a site.
Official WARN lists from California, Texas, New York, Florida, Illinois and Washington only; notices filed in other states are not shown. Matched on the employer name as filed, so a notice filed under an unrelated subsidiary name can be missing. Dates are the notice date (Washington: the date the state received it).
23 certified in FY2026 Q3, vs 23 a year earlier. 23 positions in total, median offered wage $135K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
7 approvals or clearances and 4 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.